Acknowledgement
Supported by : Khon Kaen University
References
- Buffet C, Golmard JL, Hoang C, et al (2012). Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol, 167, 267-75.
- Fernandez IJ, Piccin O, Sciascia S, et al (2013). Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngo Head and Neck Surg, 148, 919-25. https://doi.org/10.1177/0194599813481942
- Gospodarowicz MK, O'Sullivan B, Koh ES (2006). Prognostic factors: principles and applications. In: 'Prognostic factors in cancer. 3rd ed', Eds Gospodarowicz MK, O'Sullivan B, Sobin LH. John Wiley & Sons, New Jersey, 23-38.
- Guyatt G (2006). Determining prognosis and creating clinical decision rules. In 'Clinical epidemiology: how to do clinical practice research.3rd ed', Eds Haynes RB, Sackett DL, Guyatt G, et al. Lippincott Williams & Wilkins, Philadelphia, 323-55.
- Hasbek Z, Turgut B, Kilicli F, Altuntas EE, Yucel B (2014). Importance of postoperative stimulated Tg level at the time of 131I ablation therapy for differentiated thyroid cancer. Asian Pac J Cancer Prev, 15, 2523-7. https://doi.org/10.7314/APJCP.2014.15.6.2523
- Haugen BR, Alexander EK, Bible KC, et al (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26, 1-133. https://doi.org/10.1089/thy.2015.0020
- Hundahl SA, Flemming ID, Fremgen AM, Menck HR (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-48. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
- Ito Y, Kudo T, Kihara M, et al (2012). Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J, 59, 119-25. https://doi.org/10.1507/endocrj.EJ11-0288
- Kim SJ, Lee KE, Myong JP, et al (2012). BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 36, 310-7. https://doi.org/10.1007/s00268-011-1383-1
- Kim KM, Park JB, Bae KS, et al (2013). Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocr J, 60, 291-7. https://doi.org/10.1507/endocrj.EJ12-0256
- Kim WY, Kim HY, Son GS, Bae JW, Lee JB (2014). Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma. J Cancer Res Ther, 10, 50-5. https://doi.org/10.4103/0973-1482.131366
- Lee J, Song Y, Soh EY (2014). Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence. World J Surg, 38, 858-62. https://doi.org/10.1007/s00268-013-2345-6
- Mazzaferri EL, Kloos RT (2001). Current approaches to primary therapy of papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 86, 1447-63. https://doi.org/10.1210/jcem.86.4.7407
- Niemeier LA, Kuffner Akatsu H, Song C, et al (2012). A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 118, 2068-77.
- Onitilo AA, Engel JM, Lundgren CI, et al (2009). Simplifying the TNM system for clinical use in differentiated thyroid cancer. J Clin Oncol, 27, 1872-8. https://doi.org/10.1200/JCO.2008.20.2382
- Pencina MJ, D'Agostino RB (2004). Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med, 23, 2109-23. https://doi.org/10.1002/sim.1802
- Qu N, Zhang L, Ji QH, et al (2014). Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer, 14, 914. https://doi.org/10.1186/1471-2407-14-914
- Schneider DF, Mazeh H, Chen H, Sippel RS (2013). Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist, 18, 157-62. https://doi.org/10.1634/theoncologist.2012-0240
- Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD (2005). Substantial effective sample sizes were required for external validation studies of predictive logistic regression models, J Clin Epidemiol, 58, 475-83. https://doi.org/10.1016/j.jclinepi.2004.06.017
- Welsch M, Abeln M, Zaplatnikov K, et al (2007). Multiparameter scoring system for the prognosis of differentiated thyroid cancer. Nuklearmedizin, 46, 257-62.
- Xing M, AlzahraniAS, Carson KA, et al (2015). Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol, 33, 42-50.